Global expansion Novotech is expanding its footprint with new offices in Tokyo and Japan, signaling increased capacity and access to Asian trial populations. This presents opportunities to position as the CRO of choice for sponsors seeking rapid enrollment and local regulatory navigation in Asia-Pacific.

Strategic partnerships Recent collaborations with The START Center for Cancer Research and Marvel BioInfrastructure indicate a push toward early-phase oncology and neurodevelopmental programmes. Target biotech and pharma sponsors with early-phase needs and oncology pipelines to leverage Novotech’s integrated CRO and site-network strength.

Awarded reliability A long track record of Frost & Sullivan CRO Company of the Year for 19 consecutive years reinforces credibility in delivering complex trials on time. Use this to engage risk-averse clients seeking a proven partner with global reach and repeatable performance.

Clinical access network With 5,000+ trial sites and widespread Asia-Pacific, North America, and Europe access, Novotech enables diverse patient recruitment and trial efficiency. Position as the partner who can accelerate timelines by leveraging broad site access and local market insights.

Mid-market focus Serving biotech and small- to mid-sized pharma companies, Novotech aligns with sponsors needing full-service CRO support without the scale of mega-CROs. Target mid-market sponsors looking to accelerate market access with cost-effective, flexible, end-to-end solutions.